AS 602868

Drug Profile

AS 602868

Alternative Names: AS 2868; AS602868; CDC 839; SPC-839

Latest Information Update: 05 Mar 2008

Price : $50

At a glance

  • Originator Merck Serono; Signal Research Division
  • Class Anti-inflammatories; Antirheumatics; Pyrimidines; Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Haematological malignancies; Inflammation

Most Recent Events

  • 18 Feb 2008 Discontinued - Preclinical for Inflammation in USA (PO)
  • 18 Feb 2008 Discontinued - Phase-I for Haematological malignancies in USA (PO)
  • 29 Oct 2007 No development reported - Preclinical for Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top